共 50 条
- [1] A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid TumorsCLINICAL CANCER RESEARCH, 2022, 28 (05) : 882 - 892Mettu, Niharika B.Ulahannan, Susanna, VBendell, Johanna C.Garrido-Laguna, IgnacioStrickler, John H.Moore, Kathleen N.Stagg, RobertKapoun, Ann M.Faoro, LeonardoSharma, Sunil
- [2] IL believe: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon IL-2 ß/γ alone or in combination with pembrolizumab or standard-of-care chemotherapy in patients with locally advanced or metastatic solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Starodub, AlexanderGabrail, Nashat Y.Zhang, YingCastro, Davis Y. TorrejonSlavsky, SibelSingel, Stina MuiPowderly, John D.
- [3] Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Kelley, Robin KateVan Cutsem, EricLee, Michael SangminWolf, IdoFakih, MarwanDe Vos-Geelen, Judith DeLee, ValerieVogel, ArndtWu, LarryJin, FanNaik, Girish S.O'Reilly, Eileen Mary
- [4] Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)Kelley, Robin KateVan Cutsem, EricLee, Michael S.Wolf, IdoFakih, Marwande Vos-Geelen, JudithLee, ValerieVogel, ArndtWu, Xi LawrenceJin, FanNaik, Girish S.O'Reilly, Eileen Mary
- [5] A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Dudek, Arkadiusz Z.O'Shaughnessy, JoycePiha-Paul, Sarina A.Uprety, DipeshKitchens, Benjamin LeeHutson, Thomas E.Rank, Brian H.Stokes, MichaelDudgeon, CrissySurguladze, DavidLightcap, EricDrees, JeremyHarrison, BenLi, RichardLaCayo, AshleyMattson, PauletteBose, NanditaKarim, DhaminaGargano, Michele AnneIglesias, Jose Luis
- [6] A phase I, open-label study of GSK3174998 administered alone and in combination with pembrolizumab in patients (pts) with selected advanced solid tumors (ENGAGE-1)CANCER RESEARCH, 2016, 76Infante, JeffreyAhlers, Christoph M.Hodi, F. StephenPostel-Vinay, SopieSchellens, Jan H. M.Heymach, John V.Autio, KarenBarnette, MaryStruemper, HerbertWatmuff, MauraPaul, Elaine M.Kaufman, David R.Weber, Jeffrey S.Hoos, Axel
- [7] A phase 1a/1b study of STK-012, an α/β IL-2 receptor selective partial agonist as monotherapy and in combination with pembrolizumab in advanced solid tumors (NCT05098132).CANCER RESEARCH, 2022, 82 (12)Spigel, DavidSpira, AlexanderZamarin, DmitriyMcDermott, David F.Luke, JasonHeymach, John V.Previs, RebeccaSullivan, RyanGandhi, LeenaAzrilevich, AlexRizvi, NaiyerOft, MartinBusby, NatalieIzar, Benjamin
- [8] Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinomaJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)McKean, MeredithAggen, David HenryLakhani, Nehal J.Bashir, BabarLuke, Jason J.Hoffman-Censits, Jean H.Alhalabi, OmarBowman, Isaac AlexGuancial, Elizabeth A.Tan, AlanLingaraj, TruptiTimothy, MarissaKacena, KatherineMalek, Karim S.Santillana, Sergio
- [9] An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Dasari, ArvindKauh, John S.Tucci, ChristopherNanda, ShivaniKania, Marek K.Carlisle, Jennifer W.Paulson, Andrew Scott
- [10] INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Angevin, EricBarnette, Mary S.Bauer, Todd MichaelCho, Daniel C.Ellis, Catherine ElizabethGan, Hui KongHansen, Aaron RichardHoos, AxelJewell, Roxanne C.Katz, Jessica-Liberal, Juan MartinMaio, MicheleMayes, Patrick A.Millward, MichaelMoreno, VictorOlszanski, Anthony J.Rischin, DannySchellens, Jan H. M.